RxDoctor Payments Data

Bret Stysly, MD

Internal Medicine · Augusta, GANPI 1104188416

Payments from drug & device makers

$12,200in general payments, 2019–2025

Across 89 payments — averaging $137.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • Olympus Corporation Of The Americas$911
  • Veran Medical Technologies, Inc.$444
  • Boehringer Ingelheim$232
  • Insmed, Inc.$81
  • Takeda Pharmaceuticals U.S.A., Inc.$78
  • plus $348 from 12 others

What the payments were for

  • Speaking & faculty fees$4,50037%
  • Travel & lodging$5,25043%
  • Food & beverage$2,32619%
  • Education$681%
  • Gifts$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,200 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$143,269
Medicare patients
454
Services billed
1,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter625$468,224
OfevNintedanib Esylate11$141,662
Dupixent PenDupilumab28$104,424
Spiriva RespimatTiotropium Bromide175$102,391
Stiolto RespimatTiotropium Br/Olodaterol Hcl162$98,488
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr94$69,674
Spiriva HandihalerTiotropium Bromide80$65,148
Breo ElliptaFluticasone/Vilanterol128$63,061
TezspireTezepelumab-Ekko11$50,274
Dupixent SyringeDupilumab13$45,661
Incruse ElliptaUmeclidinium Bromide71$34,110
SymbicortBudesonide/Formoterol Fumarate109$28,693
Fluticasone-SalmeterolFluticasone Propion/Salmeterol216$27,108
Combivent RespimatIpratropium/Albuterol Sulfate38$24,071
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$23,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$73$643,138947 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$232$366,611386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →